Contribution of Efflux Pump Activity to the Delivery of Pulmonary Therapeutics

Authors: Hamilton K.O.; Yazdanian M.A.; Audus K.L.

Source: Current Drug Metabolism, Volume 3, Number 1, February 2002 , pp. 1-12(12)

Publisher: Bentham Science Publishers

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

To date, there are few in vitro models of the human lung that have been used to characterize multidrug resistant (MDR) efflux pump activity. It is expected that the presence of these protein transporter molecules, such as P-glycoprotein (Pgp) and the multidrug resistance protein associated protein- 1 (MRP1), might play a role in limiting drug absorption through the pulmonary epithelium, as has been reported for other epithelial drug delivery barriers such as the intestine and brain. To date, the exact role of the lung resistance related protein (LRP) in MDR is unclear. In this article, we have summarized the biochemistry, function and in vitro / in vivo modulation of Pgp and MRP1. These topics are discussed in light of pulmonary delivery of therapeutic agents, with particular emphasis being placed on the bronchial region of human airways.

Keywords: Efflux Pump; Pulmonary Therapeutics; P-glycoprotein (Pgp); lung resistance related protein (LRP); Rhodamine; Transmembrane domain; Hexakis

Language: English

Document Type: Review article

DOI: 10.2174/1389200023338170

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$55.10 plus tax Refund Policy